Dark Forest Capital Management LP Takes Position in Scholar Rock Holding Co. (NASDAQ:SRRK)

Dark Forest Capital Management LP acquired a new position in Scholar Rock Holding Co. (NASDAQ:SRRK) during the second quarter, HoldingsChannel.com reports. The fund acquired 16,181 shares of the company’s stock, valued at approximately $135,000.

Several other large investors have also added to or reduced their stakes in SRRK. AQR Capital Management LLC grew its holdings in shares of Scholar Rock by 287.2% in the 2nd quarter. AQR Capital Management LLC now owns 39,754 shares of the company’s stock valued at $331,000 after acquiring an additional 29,487 shares in the last quarter. Squarepoint Ops LLC grew its stake in Scholar Rock by 1,289.6% in the second quarter. Squarepoint Ops LLC now owns 145,060 shares of the company’s stock valued at $1,208,000 after purchasing an additional 134,621 shares in the last quarter. Cubist Systematic Strategies LLC increased its position in shares of Scholar Rock by 151.2% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 439,557 shares of the company’s stock worth $3,662,000 after purchasing an additional 264,581 shares during the last quarter. Point72 DIFC Ltd bought a new stake in shares of Scholar Rock during the 2nd quarter worth approximately $103,000. Finally, Marshall Wace LLP boosted its holdings in shares of Scholar Rock by 1,051.3% in the 2nd quarter. Marshall Wace LLP now owns 487,285 shares of the company’s stock valued at $4,059,000 after buying an additional 444,961 shares during the last quarter. Institutional investors and hedge funds own 91.08% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. HC Wainwright restated a “buy” rating and set a $30.00 target price on shares of Scholar Rock in a report on Tuesday, June 25th. Wedbush reaffirmed an “outperform” rating and issued a $23.00 target price on shares of Scholar Rock in a report on Thursday, August 8th. Finally, BMO Capital Markets raised their target price on shares of Scholar Rock from $31.00 to $34.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Scholar Rock presently has an average rating of “Buy” and an average target price of $26.43.

Scholar Rock Price Performance

NASDAQ:SRRK opened at $8.01 on Tuesday. The firm’s fifty day moving average price is $8.88 and its two-hundred day moving average price is $10.87. The company has a debt-to-equity ratio of 0.36, a current ratio of 6.04 and a quick ratio of 6.04. The company has a market cap of $638.83 million, a P/E ratio of -3.83 and a beta of 0.82. Scholar Rock Holding Co. has a one year low of $6.22 and a one year high of $21.17.

Scholar Rock (NASDAQ:SRRK) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.60) earnings per share for the quarter, beating the consensus estimate of ($0.61) by $0.01. During the same quarter in the prior year, the firm earned ($0.47) earnings per share. Equities analysts expect that Scholar Rock Holding Co. will post -2.39 earnings per share for the current year.

Scholar Rock Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.